After a comprehensive review, the Mylan board concluded the approach did not meet any of the key...
Mylan made an unsolicited $28.9 billion offer to buy the Irish drugmaker last week, but Perrigo’...
The potential combination would result in a powerhouse of a generic drug developer competing...
Mylan Executive Chairman Robert J. Coury commented, "We note that there has been some media speculation with regard to a potential bid for Mylan by Teva and that this rumor has been circulating for some time."
Sartorius Stedim Biotech (SSB), an international supplier for the biopharmaceutical industries, today acquired the Scottish company BioOutsource Ltd.
Medytox currently owns and operates several healthcare companies, including clinical testing laboratories, an electronic medical records provider, a laboratory information systems company and a medical billing company. CollabRx is a leading informatics company focused on the interpretation of complex molecular and genetic tests in cancer.
$2.0 million of preferred stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016.
Ventana, a member of the Roche Group, announced it has entered into a master collaboration agreement with Astellas Pharma Inc.
Cipher Pharmaceuticals Inc. announced it has acquired INNOCUTIS Holdings LLC, a privately held specialty dermatology company, for $45.5 million in cash.
The companies said the acquisition creates a top-tiered global OTC pharmaceutical and nutraceutical company.
Roche has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans.
Watson-Marlow Fluid Technology Group strengthens its biopharmaceutical offering through the acquisition of ASEPCO Corporation (Asepco).
Protea Biosciences Group announced today that it has entered into an agreement dated as of March 31, 2015 for the purchase of vivoPharm Pty Ltd. ("vivoPharm"), a global provider of pharmacology, toxicology and bioanalytical research services, with a portfolio of proprietary oncology models.
The closings are the latest example of a strategy shift for a company that was opening about 500 stores a year a decade ago.
Bristol-Myers Squibb has announced that it has completed its acquisition of Flexus Biosciences, Inc.
In a deal that would combine two generic drugmakers that recently left the U.S. for Europe, Mylan says it wants to buy Perrigo for $205 per share, or $28.86 billion.
Microbix Biosystems has signed an exclusive distribution agreement with Kim & Friends, Inc. The agreement provides Microbix with improved access to the key South Korean market for its virology products.
Aptalis Pharmaceutical Technologies announced today that its divestiture from Actavis plc to TPG, a global private investment firm, has been completed.
Analyst Rob Goldman says mid-stage biotech companies are being built for potential sale, in an environment of increasing mergers and acquisitions.
Patheon has closed the transaction to acquire IRIX Pharmaceuticals, a company that specializes in making difficult to manufacture Active Pharmaceutical Ingredients (API).
Valeant Pharmaceuticals International today announced it has completed the previously announced acquisition of Salix Pharmaceuticals.
Panther has licensed from Northwestern University the rights to develop and commercialize new technologies to enhance efficacy and decrease toxic side effects of a novel category of anti-cancer drugs.
Actavis PLC is selling its generic drug business in Australia to privately-held Amneal Pharmaceuticals for an undisclosed amount.
Horizon Pharma is buying Hyperion Therapeutics for about $1.1 billion, gaining two treatments for genetic disorders.
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.
The nation's largest health insurer, UnitedHealth, will muscle up for its fight against rising prescription drug costs by spending more than $12 billion to buy pharmacy benefits manager Catamaran Corp.
Sun Pharma today, begins the integration of Ranbaxy's business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.
Mergers and acquisitions in the pharmaceutical and biotechnology sectors set a record in 2014, according to a report by Evaluate Ltd.
- Page 1